Search

file (14) (1)

Investor Overview

Investor Overview

HOMEInvestor Overview

Read More

2025.Jun.27

News

Innovation in Action: OBI Pharma Sharpens Focus on ADC Products, Platforms, and Out-Licensing
Integrating Product and Platform Capabilities to Drive Global Collaboration

2025.Jun.10

News

OBI Pharma Showcases Next-Generation ADC Development at 2025 World ADC Asia Summit

2025.Jun.06

News

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies

Read More

2025.Jul.18

Announcement

OBI-902 TROP2 ADC has been granted by the TFDA to proceed to Phase I/II human clinical trial

2025.Jun.27

Announcement

Announcement of 1st Sustainable Development Committee Members

2025.Jun.27

Announcement

Announcement of 6th Remuneration and Nomination Committee Members

2024 Annual Report

Learn how we created value in 2024 and worked to pursue our purpose of enabling a healthier world.

Download PDF
Read More

Featured
Presentation

2025 Investors' Meeting - Innovation in Action

Download PDF

Read More

2025 Annual Shareholders’ Meeting

  • 2025.Jun.27 at 10:00 AM
  • Taipei Bioinnovation Park 1F Conference Room

Governance

Read More

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations

Contact